Advertisement

International Journal of Colorectal Disease

, Volume 33, Issue 8, pp 1107–1114 | Cite as

Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer

  • Qi Liu
  • Yanlei Ma
  • Dakui Luo
  • Sanjun Cai
  • Qingguo Li
  • Xinxiang Li
Original Article

Abstract

Purpose

This study aimed to improve the American Joint Committee on Cancer (AJCC) Tumor Node Metastases (TNM) staging system and demonstrate the improvement in prognostic accuracy and clinical management guidance in colon cancer using the novel prognostic score (P score).

Methods

Eligible patients were identified using the Surveillance, Epidemiology, and End Results database. A P score (based on age, tumor size, and tumor grade) was assigned to each patient. The Cox proportional hazards regression analyses were performed to identify independent factors associated with prognosis. The Kaplan–Meier survival curves were used to analyze the prognosis of patients with colon cancer with different P scores. The TNM staging system was compared with the P score in stages I–IV by calculating the concordance index.

Results

The multivariate Cox analysis indicated that a higher P score was independently associated with a higher risk of cancer-specific mortality. The Kaplan–Meier survival curves showed that the survival benefit gradually increased as the P score decreased. The concordance index rose from 0.5, 0.593, 0.633, and 0.551 of AJCC TNM staging system to 0.709, 0.651, 0.691, and 0.623 of P score in stages I–IV, respectively.

Conclusions

The P score was an independent prognostic factor of colon cancer and had a much better prognostic accuracy than the AJCC TNM staging system in all patients with colon cancer. It may help in identifying patients with high-risk stage II colon cancer who were candidates for adjuvant therapy and differentiating patients with stage III colon cancer for adjuvant therapy.

Keywords

Prognostic score Stage II Stage III Colon cancer SEER 

Notes

Acknowledgments

The authors acknowledge the effort that went into compiling and maintaining the Surveillance, Epidemiology, and End Results Program (SEER) tumor registries, including the interpretation and reporting of these data.

Funding

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81702353 and 81772599) and Shanghai Municipal Natural Science Foundation (17ZR1406400). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical standards

Competing interests

The authors declare that they have no conflicts of interest.

Supplementary material

384_2018_3071_MOESM1_ESM.docx (17 kb)
ESM 1 (DOCX 17 kb)

References

  1. 1.
    Siegel RL et al (1900) Colorectal cancer statistics, 2017. CA Cancer J Clin 64(2):104–117CrossRefGoogle Scholar
  2. 2.
    Weiser MR et al (2011) Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol Off J Am Soc Clin Oncol 29(36):4796–4802CrossRefGoogle Scholar
  3. 3.
    Arena EA, Bilchik AJ (2013) What is the optimal means of staging colon cancer? Adv Surg 47(1):199–211CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Auclin E et al (2017) Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol Off J Euro Soc Med Oncol 28(5):mdx030CrossRefGoogle Scholar
  5. 5.
    Kune GA et al (1990) Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 33(11):938CrossRefPubMedGoogle Scholar
  6. 6.
    Aquina CT, Mohile SG, Tejani MA, Becerra AZ, Xu Z, Hensley BJ, Arsalani-Zadeh R, Boscoe FP, Schymura MJ, Noyes K, Monson JRT, Fleming FJ (2017) The impact of age on complications, survival, and cause of death following colon cancer surgery. Br J Cancer 116:389–397CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mulcahy HE et al (1994) Prognosis of elderly patients with large bowel cancer. Br J Surg 81(5):736CrossRefPubMedGoogle Scholar
  8. 8.
    Patel SS et al (2013) Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer 119(4):739CrossRefPubMedGoogle Scholar
  9. 9.
    Yamano T et al (2017) Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: a retrospective multicentre study. Eur J Cancer 81:90CrossRefPubMedGoogle Scholar
  10. 10.
    Li Q et al (2014) Better long-term survival in young patients with non-metastatic colorectal cancer after surgery, an analysis of 69,835 patients in SEER database. Plos One 9(4):e93756CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cerottini JP et al (1999) Prognostic factors in colorectal cancer. Oncol Rep 6(2):409–414PubMedGoogle Scholar
  12. 12.
    Phillips MRKS et al (1984) Large bowel cancer: surgical pathology and its relationship to survival. Br J Surg 71(8):604CrossRefPubMedGoogle Scholar
  13. 13.
    Gill S et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol Off J Am Soc Clin Oncol 22(10):1797CrossRefGoogle Scholar
  14. 14.
    Kornprat P et al (2011) Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol 34(1):43CrossRefPubMedGoogle Scholar
  15. 15.
    Saha S et al. (2012) Tumor size as a prognostic factor for patients with colon cancer undergoing sentinel lymph node mapping and conventional surgery. Ann Surg Oncol. 20(4): p. -Google Scholar
  16. 16.
    Saha S et al (2015) Tumor size predicts long-term survival in colon cancer: an analysis of the National Cancer Data Base. Am J Surg 209(3):570CrossRefPubMedGoogle Scholar
  17. 17.
    Harrell FE et al (1982) Evaluating the yield of medical tests. JAMA 247(18):2543–2546CrossRefPubMedGoogle Scholar
  18. 18.
    Manilich EA et al (2011) A novel data-driven prognostic model for staging of colorectal cancer. J Am Coll Surg 213(5):579–588.e2CrossRefPubMedGoogle Scholar
  19. 19.
    Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group (2014) ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst 106(12):dju333CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Benson AB et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol Off J Am Soc Clin Oncol 22(16):3408CrossRefGoogle Scholar
  21. 21.
    Casadaban L et al (2016) Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer 122(21):3277–3287CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    O'Connor ES et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol Off J Am Soc Clin Oncol 29(25):3381–3388CrossRefGoogle Scholar
  23. 23.
    Verhoeff SR et al (2016) Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer 139(1):187–193CrossRefPubMedGoogle Scholar
  24. 24.
    Benson AB et al (2011) NCCN clinical practice guidelines in oncology: colon cancer version 1:2012. J Natl Compr Cancer Netw 9(11):1238–1290CrossRefGoogle Scholar
  25. 25.
    Labianca R et al (2013) Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Euro Soc Med Oncol 24(Suppl 6(3)):vi64Google Scholar
  26. 26.
    Chau I et al (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol Off J Euro Soc Med Oncol 16(4):549CrossRefGoogle Scholar
  27. 27.
    Lonardi S et al (2016) Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol Off J Euro Soc Med Oncol 27(11):mdw404Google Scholar
  28. 28.
    Cramptom P, Williams R (2009) Adjuvant chemotherapy for stage II colon cancer: the role of molecular markers in choosing therapy. Gastrointest Cancer Res 3(5):191–196Google Scholar
  29. 29.
    Clarklangone KM et al (2010) Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX® Colon Cancer Assay. BMC Cancer 10(1):691CrossRefGoogle Scholar
  30. 30.
    Roth AD et al (2012) Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 104(21):1635CrossRefPubMedGoogle Scholar
  31. 31.
    Kwon KA et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10(1):203–203CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Romanus D et al (2009) Concordance with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures: an NCCN institutional analysis. J Natl Compr Cancer Netw 7(8):895–904CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Colorectal SurgeryFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations